[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Loyola University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":418},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,39,71,84,111,133,162,192,217,246,267,296,324,350,372,391],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100054116","assessing-the-effect-of-an-aerobic-exercise-program-on-vascular-function-in-women-with-non-metastatic-breast-cancer-100054116",false,"NCT07517224","Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer","Inclusion criteria:\n\n1. Women (18-70 years) with a stage I-III breast cancer diagnosis who have completed chemotherapies.\n2. Able to begin aerobic exercise within 4 weeks of the final chemotherapy cycle.\n3. Sedentary by self-reporting inactivity (\\\u003C90 min of moderate or vigorous exercise per week)\n4. Weight ≤154 kg\n5. Willing to complete all study activities\n6. Able to safely participate in moderate aerobic exercise.\n\nExclusion criteria:\n\n1. Current pregnant and lactating patients. Must have completed lactation prior to study start.\n2. Metastatic disease.\n3. Diagnosed cardiovascular disease prior to the initiation of chemotherapy, as evidenced by cardiomyopathy (reduced regional or global left ventricular contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%.\n4. History of prior chemotherapy received for other cancer diagnosis.\n5. Non-English speaking","FEMALE","18 Years","70 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to assess the feasibility of an 8-week aerobic exercise program and its effect on arterial function in breast cancer survivors.\n\nThe main questions it aims to answer are:\n\n* Is an 8-week aerobic exercise program feasible in breast cancer survivors after the completion of chemotherapy?\n* Is this 8-week aerobic exercise program beneficial for vascular function in breast cancer survivors?\n\nParticipants will:\n\n* Begin an 8-week aerobic exercise program, three days per week, after the completion of chemotherapy.\n* Visit our facility three times before the exercise program, 1 month after, and after the completion of the program.\n* Complete questionnaires, physical functional tests, and body composition and vascular measurements at every visit.",[26],"Breast Cancer Survivors","NOT_YET_RECRUITING","2026-07-09",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-08-01",{"date":35,"type":20},"2035-05-01",{"name":37,"class":38},"Loyola University","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":47,"briefSummary":48,"conditions":49,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100631230","utilizing-electronic-modules-to-educate-on-sexual-health-practices-during-pregnancy-100631230","NCT07497971","Utilizing Electronic Modules to Educate on Sexual Health Practices During Pregnancy","Inclusion Criteria:\n\n* Pregnant individuals at or beyond 12 weeks gestation\n* Age 18 years or older\n* English speaking with English reading proficiency\n* Experiencing a low risk pregnancy with no major complications\n* Not currently followed by Maternal-Fetal Medicine (MFM) for high risk pregnancy management\n\nExclusion Criteria:\n\n* Pregnancy complications requiring management by Maternal-Fetal Medicine (MFM)\n* Placed on pelvic rest\n* Advised by their provider to abstain from sexual intercourse",{"count":46,"type":20},100,[23],"This study looks at whether an interactive online education module can improve knowledge, comfort, and communication about sexual health during pregnancy. Many pregnant individuals experience changes in sexual function and intimacy but may feel uncomfortable discussing these topics or may have misconceptions about what is safe during pregnancy.\n\nParticipants who are pregnant and receiving routine prenatal care will be randomly assigned to one of two groups. One group will complete an interactive, evidence-based educational module focused on sexual health and intimacy during pregnancy. The other group will review a standard educational article from the American College of Obstetricians and Gynecologists (ACOG) about sexual activity during pregnancy.\n\nParticipants will complete surveys before and after reviewing the educational material, as well as a follow-up survey two weeks later. These surveys will measure knowledge about sexual health during pregnancy, comfort discussing sexual concerns with healthcare providers, and sexual function. The goal of this study is to determine whether an interactive educational approach can better support pregnant individuals' understanding of sexual health and encourage open communication with healthcare providers during pregnancy.",[50,51,52],"Sexual Health Education During Pregnancy","Communication About Sexual Health in Prenatal Care","Sexual Function and Intimacy in Pregnancy",[54,55,56,57,58,59,60,61],"Pregnancy","Sexual health","Prenatal education","Patient education","Digital health education","Female Sexual Function Index","Communication with healthcare providers","Intimacy","2026-04-13",{"date":64,"type":31},"2026-04-16",{"date":66,"type":20},"2026-05",{"date":68,"type":20},"2027-02",{"name":37,"class":38},1,{"id":72,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":24,"conditions":76,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":4},"100632710","Inclusion Criteria:\n\n1. Women (18+ years) with a stage I-III breast cancer diagnosis who have completed chemotherapies.\n2. Completed the final chemotherapy cycle within the past 4 weeks.\n3. Sedentary by self-reporting inactivity (\\\u003C90 min of moderate or vigorous exercise per week)\n4. Body mass index ≤40 kg\u002Fm²\n5. Willing to complete all study activities\n6. Able to safely participate in moderate aerobic exercise.\n\nExclusion Criteria:\n\n1. Current pregnant and lactating patients. Must have completed lactation prior to study start.\n2. Metastatic disease.\n3. Diagnosed cardiovascular disease prior to the initiation of chemotherapy, as evidenced by cardiomyopathy (reduced regional or global left ventricular contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%.\n4. History of prior chemotherapy received for other cancer diagnosis.\n5. Non-English speaking",{"count":19,"type":20},[23],[26],"2026-04-03",{"date":79,"type":31},"2026-04-08",{"date":81,"type":20},"2026-05-01",{"date":35,"type":20},{"name":37,"class":38},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100609598","multisensory-early-oral-administration-of-human-milk-m-milk-for-very-preterm-infants-100609598","NCT07216664","Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants","Randomized Controlled Trial of Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants: Enhancing Stress Regulation, Neurodevelopment, and Oral Feeding Skills","M-MILK RCT","Inclusion Criteria:\n\n* Born at ≤ 32 weeks gestational age.\n* Receiving mother's own milk and\u002For donor human milk at the time of screening.\n\nExclusion Criteria:\n\n* Receiving only formula.\n* Gastrointestinal defects, i.e., cleft lip or cleft palate.\n* Congenital cardiac defects requiring surgery.\n* Necrotizing enterocolitis.\n* Chromosomal abnormalities.","ALL","23 Weeks","32 Weeks",{"count":96,"type":20},125,[23],"The goal of this clinical trial is to learn if the multisensory early oral administration of human milk (M-MILK) intervention helps infants who are born younger than 32 weeks gestational age (very preterm infants). The main question that this clinical trial aims to answer is: Does M-MILK improve stress regulation, support optimal neurodevelopment, and promote competent oral feeding skills in very preterm infants?\n\nResearchers will compare M-MILK to the standard of care to see if M-MILK helps very preterm infants. Specifically, researchers will compare the differences in:\n\n* Cortisol levels\n* DNA methylation of the two stress related genes (NR3C1 and HSD11B2)\n* Neurodevelopment\n* Oral feeding skills Participants in the M-MILK group will receive standard of care plus M-MILK intervention, which starts on day 3 of life and continues until they begin their oral feeding. M-MILK will be provided by clinical research nurses, during the day shift, up to 4 times a day. Participants in the standard of care group will continue to receive their usual care.",[100],"Infant, Premature, Diseases","RECRUITING","2026-01-16",{"date":104,"type":31},"2026-01-20",{"date":106,"type":31},"2025-11-03",{"date":108,"type":20},"2031-05-31",{"name":37,"class":38},2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":92,"minAge":16,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100553486","mechanical-alignment-versus-kinematic-alignment-total-knee-arthroplasty-100553486","NCT06486714","Mechanical Alignment Versus Kinematic Alignment Total Knee Arthroplasty","Mechanical Alignment Versus Kinematic Alignment Total Knee Arthroplasty: A Randomized Control Trial","Inclusion Criteria:\n\n* Patients 18 years or older presenting to our institutions indicated for a primary total knee arthroplasty\n\nExclusion Criteria:\n\n* Revision TKA\n* Patients with prior injuries to study knee\n* Patients with history of childhood knee disease\n* Patients who cannot complete questionnaires in English\n* Patients with comorbidities preventing surgery\n* Patients who are not able to provide informed consent",true,{"count":120,"type":20},96,[23],"Historically, total knee arthroplasty (TKA) has been performed with the goal of restoring a neutral mechanical axis, eliminating the average 3 degrees of valgus and varus of the distal femur and proximal tibia joint lines respectively. This is thought to provide a more stable and neutral joint-bearing surface. Because of this shift to a 0-degree knee angle, soft tissue releases are frequently required to balance the knee after making the distal tibia and proximal tibia cuts. More recently and increasingly, TKAs have been performed with a goal of restoring kinematic, or anatomic, alignment of the knee. This is thought to provide a more normal native knee angle, with the hopes of precluding the necessity of soft tissue releases to balance the knee. While some studies are promising regarding kinematically aligned TKAs (KA-TKA), at present, it is unclear how these compare to mechanically aligned TKAs (MA-TKA) in terms of patient reported outcome measures (PROM) when compared head-to-head.\n\nThis study will randomize patients to receive either cemented MA-TKA or KA-TKA with the goal of assessing pain scores and PROMs at various time points following surgery.",[124],"Knee Osteoarthritis","2025-12-02",{"date":127,"type":31},"2025-12-09",{"date":129,"type":20},"2026-03-01",{"date":131,"type":20},"2027-06-30",{"name":37,"class":38},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":92,"minAge":16,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":150,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":70},"100610355","effects-of-core-strengthening-exercises-for-treating-tmd-100610355","NCT07226505","Effects of Core Strengthening Exercises for Treating TMD","A Randomized Trial Analyzing the Effects of Core Strengthening Exercises in Physical Therapy for Treating Temporomandibular Joint Dysfunction","Who Can Participate (Inclusion Criteria):\n\nAdults between 18 and 70 years old.\n\nHave had jaw pain or problems with the jaw joint (TMD) in the last 30 days.\n\nAble and willing to attend at least six physical therapy sessions over three months.\n\nSpeak English or have access to a qualified interpreter.\n\nAble to safely do physical exercises.\n\nWho Cannot Participate (Exclusion Criteria):\n\nRecently had surgery on the jaw, teeth, or spine (within the last 3 months).\n\nRecently had head or neck injuries or certain neurological problems (such as dizziness, double vision, trouble swallowing, or sudden falls).\n\nAre pregnant or become pregnant during the study.\n\nCurrently doing physical therapy for other movement problems that could affect the study.\n\nHave had lower back or pelvic health issues in the last 3 months.\n\nCurrently receiving chemotherapy or radiation for cancer in the head, neck, pelvis, spine, or hip.\n\nWear dentures or cannot safely perform exercises.","80 Years",{"count":142,"type":20},50,[23],"Temporomandibular disorders (TMD) are commonly managed with non-invasive interventions such as manual therapy, therapeutic exercise, relaxation techniques, and patient education. Core strengthening (also known as abdominal strengthening) is a fundamental element of physical therapy that engages deep and superficial trunk musculature to enhance postural control and functional performance. Protocols such as the Shirley Sahrmann progression have demonstrated increased activation of key core stabilizing muscles. Emerging evidence suggests a potential relationship between core stability training and reductions in TMD-related pain, though improvements in functional outcomes remain inconclusive. Biomechanical links between the pelvic floor, spine, and temporomandibular joint further support the rationale for core-focused interventions. Nevertheless, few studies have isolated the effects of core strengthening on TMD symptomatology. This study seeks to determine whether the integration of core stability exercises into TMD management can reduce pain, improve function, and enhance quality of life.",[146,147,148,149],"Temporomandibular Joint Dysfunction","TMD","TMJ Internal Derangement","Myofascial Pain",[151,152,153],"Core strengthening","physical therapy","RCT","2025-11-07",{"date":156,"type":31},"2025-11-10",{"date":158,"type":20},"2025-11-01",{"date":160,"type":20},"2027-01-31",{"name":37,"class":38},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":92,"minAge":170,"maxAge":17,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":70},"100537949","phase-4-ketamine-as-a-supplement-to-local-anesthesia-for-minor-procedures-100537949","NCT06284473","Ketamine as a Supplement to Local Anesthesia for Minor Procedures","Intranasal Ketamine as a Supplement to Local Anesthesia to Reduce Pain Associated With Minor Procedures in the Emergency Department","INK-MP","Inclusion Criteria:\n\n* Undergoing Minor Procedure in the ED\n* Weight not to exceed 115kg\n\nExclusion Criteria:\n\n* Altered Mental Status\n* Pregnancy\n* Breastfeeding\n* Acute head or eye injury\n* Intercranial Hypertension\n* Hx of seizures\n* Hx of chronic pain\n* Unstable vital signs\n* Allergy to Ketamine\n* Hepatic or Renal Insufficiency\n* Hx of Psychiatric Illness\n* Hx of alcohol\u002Fdrug abuse","7 Years",{"count":172,"type":20},108,[174],"PHASE4","This trial is a double-blind randomized controlled clinical trial of adults and children (ages 7 to less than 70 years). Patients who present to the ED and who undergo minor bedside procedures that require local anesthesia will be divided into two groups: The first group will be treated with 0.7 mg\u002Fkg intranasal ketamine as well as standard local anesthesia for the procedure (treatment cohort). The second group will be treated with a volume-based dose of intranasal saline solution as well as standard local anesthesia for the procedure (control cohort). The primary aim is to assess whether patients in the treatment cohort report lower pain scores on the Numerical Rating Scale (NRS-100) when compared to patients in the control cohort. For adult patients, a secondary aim is to compare agitation between the two cohorts using the Richmond Agitation Sedation Scale (RASS) and, for pediatric patients, a secondary aim is to compare alertness between the two cohorts using the University of Michigan Sedation Scale (UMSS).\n\nResults obtained from specific procedures will be analyzed on a spectrum of complexity and general length of recovery time. Scientific achievements may include finding a safe and effective way to reduce pain and discomfort during minor procedures in the Emergency Department. Additionally, it would provide opportunities for more research on sub-dissociative doses of ketamine during minor procedures: a topic in which there is still a gap in the published research",[177,178,179],"Pain, Procedural","Minor Laceration","Abscess",[181,182,183],"IN Ketamine","Sub-dissociative dose","Minor procedure","2025-09-30",{"date":186,"type":31},"2025-10-03",{"date":188,"type":31},"2022-05-25",{"date":190,"type":20},"2028-05-31",{"name":37,"class":38},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":15,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":70},"100508616","the-impact-of-a-race-based-stress-reduction-intervention-100508616","NCT05902741","The Impact of a Race-Based Stress Reduction Intervention","The Impact of a Race-Based Stress Reduction Intervention on Well-Being, Inflammation, and DNA Methylation in African American Women at Risk for Cardiometabolic Disease","Inclusion Criteria:\n\n* Between the ages of 50 and 75\n* Female\n* Post-menopausal (without menstrual period for at least 12 consecutive months)\n* Self-identified AA or Black\n* Able to write, read, speak English\n* Must have at least 1 of any of the following:\n\n  * Waist circumference \\>88 cm\n  * Systolic BP\\>130 mmHg and\u002F or diastolic BP\\>88 mmHg or on antihypertensive medications\n  * Diagnosed and\u002For being treated for hypercholesterolemia\n  * History of Type 2 diabetes\n\nExclusion Criteria:\n\n* History of myocardial infarction or ischemic heart disease\u002Fangina, stent placement, coronary artery bypass, left ventricular hypertrophy, congestive heart failure, or ischemic stroke\n* Any major immune-related disease (e.g., rheumatoid arthritis. lupus)\n* Use of immune-altering medications, such as glucocorticoids\n* Periodontal disease, bleeding gums, dental work in past 72 hours\n* Current smoker or has smoked in past 3 months\n* Active cancer\n* Active infection\n* Substance abuse\n* Cognitive or psychiatric disorder that would affect ability to participate in classes (Brief Screen for Cognitive Impairment total score of 8 or higher)","50 Years","75 Years",{"count":202,"type":20},300,[23],"The goal of this clinical trial is to learn whether a stress reduction program called Resilience, Stress, and Ethnicity (RiSE) improves well-being, inflammation, and the epigenome in African American (AA) women who have risk factors for heart or metabolic disease.\n\nThe main question it aims to answer is whether an intervention that integrates cognitive-behavioral strategies focused on the impact that social stress, such as racism, has on the body, racial identity development, and empowerment.\n\nParticipants will placed in one of the two following groups:\n\n* The RiSE program will focus on teaching participants how to reduce their stress levels and will meet online weekly for approximately 2 hours each week for 8 consecutive weeks.\n* The Health Education program will include education on how to improve general health and will meet online weekly for approximately 2 hours each week for 8 consecutive weeks.\n\nParticipants will provide saliva to measure cytokines and DNA methylation (DNAm), complete questionnaires, and have blood pressure, heart rate, and weight measured at the following clinic visits:\n\n1. Prior to starting the intervention\n2. Mid-way through the intervention (Week 4)\n3. End of the intervention (Week 8)\n4. Six (6) months after the completion of the intervention",[206,207,208],"Racism","Stress","Inflammation","2025-09-02",{"date":211,"type":31},"2025-09-09",{"date":213,"type":31},"2023-10-18",{"date":215,"type":20},"2028-01-31",{"name":37,"class":38},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":92,"minAge":16,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":226,"phases":4,"briefSummary":227,"conditions":228,"keywords":232,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":70},"100495267","renal-mass-biopsy-peer-and-99mtc-sestamibi-spectct-for-patients-with-clinically-localized-renal-tumors-100495267","NCT05728957","Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT\u002FCT for Patients With Clinically Localized Renal Tumors","A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT\u002FCT for Patients With Clinically Localized Renal Tumors","BIOPSy","Inclusion Criteria:\n\n* Participants diagnosed with a clinically localized (cT1) renal tumor ≤7cm in size with a solid component suspicious for malignancy based on cross-sectional imaging\n* Pre-existing CT images of the mass with and without contrast or planned CT to ensure both with and without contrast images of the mass have been obtained within a 365-day window\n* Participants must be greater than or equal to 18 years of age\n* Eligible or planned to undergo partial or radical nephrectomy as determined by primary urologist\n* Eligible or planned to receive renal mass biopsy as determined by primary urologist\n* Estimated glomerular filtration rate of ≥30 ml\u002Fmin\u002F1.73 m2 as calculated by the CKD-EPI (Chronic Kidney Disease-Epidemiology Collaboration) Equation\n\nExclusion Criteria:\n\n* Participants must not be pregnant (as determined by local policy by radiology \u002F imaging center)\n* Participants must not have evidence of clinical nodal or distant metastasis.\n* Participants must not have had a history of other malignancy with concern for renal metastasis.\n* Participants must not have any known allergy to technetium or sestamibi.",{"count":46,"type":20},"OBSERVATIONAL","The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor.\n\nThe main objectives are:\n\nTo estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT\u002FCT (with renal mass biopsy for hot tumors) to differentiate malignant and benign renal tumors.\n\nTo estimate and compare the diagnostic accuracy of renal mass biopsy, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT\u002FCT (with renal mass biopsy for hot tumors) to differentiate oncocytoma from chromophobe RCC.\n\nParticipants will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. These can be done on paper, electronically, or by telephone.",[229,230,231],"Kidney Tumor","Renal Benign Neoplasm","Renal Malignant Tumor",[229,233,234,235,230,231,236,237],"Survey Questions","Benign","Malignant","Nuclear Imaging","Computed Tomography","2025-03-17",{"date":240,"type":31},"2025-03-19",{"date":242,"type":31},"2023-02-01",{"date":244,"type":20},"2033-12",{"name":37,"class":38},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":15,"minAge":253,"maxAge":140,"enrollmentInfo":254,"targetDuration":4,"studyType":226,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":70},"100496897","musculoskeletal-and-pelvic-floor-health-in-female-chronic-overlapping-pelvic-pain-conditions-100496897","NCT05750212","Musculoskeletal and Pelvic Floor Health in Female Chronic Overlapping Pelvic Pain Conditions","Musculoskeletal and Pelvic Floor Health in Female Chronic Overlapping Pelvic Pain Conditions (The MSK-PELVIC Study)","Inclusion Criteria:\n\n* Female sex\n* Age 21 to 80 years\n* Symptoms of CPP as defined by the American College of Obstetrics \\& Gynecology (ACOG) for more than 6 months\n* At least two of seven overlapping CPP diagnosis (i.e., IC\u002FPBS, IBS, Endometriosis, Vulvodynia, PN, FM, PFMP)\n* An average CPP pain score of at least three on a 10 point pain scale\n\nExclusion Criteria:\n\n* Current or history of GI or GU pelvic cancer\n* Current pelvic infection (e.g., a UTI or vaginal infection)\n* Current or imminent planned pregnancy or recent delivery in the last 6 months\n* Abdominal or pelvic surgery in the last 36 months.","21 Years",{"count":255,"type":20},208,"The purpose of this study is to learn about nerve function and pelvic muscle function. To do this we will compare the pelvic nerve and muscle function of women with chronic pelvic pain to those who do not have chronic pelvic pain. Understanding the pain may lead to better treatments in the future.",[258],"Chronic Pelvic Pain Syndrome","2025-03-06",{"date":261,"type":31},"2025-03-10",{"date":263,"type":31},"2023-01-24",{"date":265,"type":20},"2025-10-24",{"name":37,"class":38},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":92,"minAge":16,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":70},"100502636","phase-4-buprenorphine-clonidine-and-dexamethasone-on-duration-of-brachial-plexus-blocks-for-upper-extremity-surgery-100502636","NCT05824832","Buprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery","Effects of a Triple Adjuvant Combination of Buprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery, a Prospective, Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients ≥ 18 years old\n* Patients undergoing shoulder arthroscopy\n* Patients willing to participate and sign informed consent\n\nExclusion Criteria:\n\n* Severe COPD\u002Fother contraindication to general anesthesia\n* Patient with a weight of less than 60 kg\n* Dementia, not alert or oriented to person, place, or time\n* Chronic pain patient with daily opioid use at home.\n* Patient with allergy to local anesthetics\n* Patient refusal\n* Total shoulder arthroplasty\n* Concomitant pain in different area from operative site.\n* Pregnancy\n* Patient with active infection on the injection sites for the blocks\n* Patients unable or willing to understand or comply with the study protocol",{"count":275,"type":20},120,[174],"The goal of this clinical trial is to learn if there is a difference in morphine requirements in patients after upper extremity surgeries including shoulder arthroscopy. The main question it aims to answer is whether there is a difference between Interscalene brachial plexus blocks with the addition of buprenorphine, dexamethasone, and clonidine and the same block without the adjuvant.",[279],"Pain, Postoperative",[281,282,283,284,285,286,287],"buprenorphine","clonidine","dexamethasone","brachial plexus blocks","pain","shoulder","surgery","2025-03-04",{"date":290,"type":31},"2025-03-07",{"date":292,"type":31},"2023-02-28",{"date":294,"type":20},"2026-06-30",{"name":37,"class":38},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":305,"briefSummary":307,"conditions":308,"keywords":312,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":70},"100563679","phase-3-rct-glargine-vs-nph-for-treatment-of-dm-in-pregnancy-100563679","NCT06619301","RCT Glargine vs NPH for Treatment of DM in Pregnancy","Randomized Controlled Trial of Glargine Versus Neutral Protamine Hagedorn Insulin for the Treatment of Diabetes Mellitus in Pregnancy","Inclusion Criteria:\n\n* Patient requiring initiation of insulin therapy for Gestational Diabetes Mellitus or Type 2 Diabetes Mellitus in pregnancy\n* At least 18 years old\n* Insulin started prior to 34 weeks gestation\n* Established prenatal care by 14 weeks gestation\n\nExclusion Criteria:\n\n* Those under the age of 18 years old\n* Those unable to consent in english\n* Allergy to insulin\n* Controlled with only diet modification or the use of oral antihyperglycemics\n* Has diagnosis of Type 1 Diabetes Mellitus\n* Receiving insulin through an insulin pump",{"count":304,"type":20},160,[306],"PHASE3","We are asking you to take part in this research study because you are diagnosed with pregestational Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus requiring insulin therapy in pregnancy. Currently, many hospitals differ among use of insulin for management of DM in pregnancy, with NPH, glargine and detemir being the most commonly used forms of basal insulin. Outside of pregnancy, NPH is rarely used with glargine and determir being the more common forms of insulin used due to their fewer episodes of hypoglycemia in these patients. Detemir has been well studied in pregnancy and found to be noninferior to NPH. Unfortunately, glargine has not been as well studied in pregnancy. Thus, with this study we want to compare glargine and NPH.\n\nThe purpose of this study is to compare two different forms of insulin (Glargine and NPH) that we regularly use to manage diabetes mellitus in pregnancy.",[309,310,311],"Diabetes Mellitus in Pregnancy","Type 2 Diabetes Mellitus (T2DM)","Gestational Diabetes Mellitus, Class A2",[313,314,315],"Glargine","NPH","Hypoglycemia","2024-09-26",{"date":318,"type":31},"2024-10-01",{"date":320,"type":31},"2024-04-01",{"date":322,"type":20},"2027-01-01",{"name":37,"class":38},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":92,"minAge":16,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":332,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":70},"100514805","phase-2-decitabine-and-selinexor-in-combination-to-reverse-drug-resistance-with-standard-chemotherapy-in-ovarian-cancer-100514805","NCT05983276","Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer","Combination of the Hypomethylating Agent Decitabine and the Nuclear Export Receptor XPO-1 Inhibitor Selinexor to Reverse Platinum Resistance in Relapsed\u002FRefractory Epithelial Ovarian Cancer","Inclusion Criteria:\n\n* Participants must be greater than or equal to 18 years of age\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status PS less than or equal to 2.\n* Participants must have histological or cytological proven epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma with relapse or disease progression after prior treatment by exam, computed tomography (CT), PET\u002FCT, or magnetic resonance imaging (MRI) may be enrolled. All cell types including clear cell carcinoma are eligible.\n* Participants must have failed or relapsed after a platinum and taxane containing combination\n* Participants must have adequate hepatic function\n* Participants must have adequate renal function\n* Participants must be able to swallow and retain oral medications\n* Participants must have measurable disease according to Gynecologic Cancer Intergroup CA125 criteria\n* Participants with stable (for 2 months or longer), treated (by radiotherapy) CNS metastases are eligible\n* Participants with active hepatitis B virus (Hep B) are allowed if antiviral therapy for hepatitis B has been given for greater than 8 weeks.\n\nExclusion Criteria:\n\n* Participants must not have received Selinexor or another XPO1 inhibitor previously.\n* Participants must not have had any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.)\n* Participants must not have uncontrolled active infection. Participants on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n* Participants must not have known intolerance, hypersensitivity, or contraindication to platinum or taxane therapy\n* Participants must not have active, unstable cardiovascular function\n* Participants must not have myocardial infarction within 3 months prior to starting\n* Participants with untreated central nervous system (CNS) metastases are ineligible.\n* Participants must not have had prior chemotherapy or radiation therapy\n* Participants must not have DVT related to metastatic disease requiring ongoing anticoagulation.",{"count":19,"type":20},[333],"PHASE2","The goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and paclitaxel) on patients with relapsed ovarian, fallopian or primary peritoneal carcinoma.\n\nRecently the investigators have found that the combination of decitabine and selinexor, two Food and Drug Administration (FDA) approved chemotherapy agents, may prevent or reverse the development of drug resistance and further the remissions and duration of remissions with standard ovarian cancer chemotherapy with carboplatin and paclitaxel. As decitabine and selinexor are not FDA approved for the participant's cancer, these agents are investigational.",[336],"Ovarian Cancer",[336,338,339,340,341],"Platinum Resistance","Relapsed\u002FRefractory Epithelial","Fallopian Tube","Primary Peritoneal Cancer","2024-02-07",{"date":344,"type":31},"2024-02-08",{"date":346,"type":31},"2023-11-16",{"date":348,"type":20},"2031-08-28",{"name":37,"class":38},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":92,"minAge":357,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":21,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":369,"leadSponsor":371,"locationsCount":70},"100514986","phase-4-ipack-on-early-pain-scores-after-acl-reconstruction-100514986","NCT05985629","IPACK on Early Pain Scores After ACL Reconstruction","The Effect of IPACK Nerve Blocks on Early ACL Pain Scores","Inclusion Criteria:\n\n* All patients presenting to Dr. John Miller with the Department of Orthopedic Surgery, Sports Medicine Division, at Loyola University Medical Center electing to undergo ACL reconstruction surgery.\n* Patients 16 and over\n* English speaking patients\n* Patients who have the capacity to make their own medical decisions and consent to the study\n\nExclusion Criteria:\n\n* Previous surgery on the operative knee\n* Previous knee infection\n* Chronic opioid use\n* Have a known allergy to local anesthetics\n* Patient using autograft (cadaver) for ACL reconstruction.","16 Years",{"count":359,"type":20},78,[174],"The goal of this clinical trial is to learn whether using an anesthetic technique called IPACK block will control pain after ACL reconstruction surgery. The main questions it aims to answer are:\n\n* if participants who receive the IPACK block prior to ACL reconstruction experience less pain after surgery and at 1 day after surgery\n* if participants who receive the IPACK block prior to ACL reconstruction require less short-term opioid use immediately after surgery and up to one week after surgery.\n\nParticipants will be randomized 1:1 to 1 of 2 groups: Use of IPACK block during ACL reconstruction vs. placebo (a placebo is a look-alike substance that contains no active drug). Neither the participant nor the investigator will know which group the participants has been assigned to.\n\nResearchers will compare self-reported pain scores and short-term opioid use of all study participants.",[279,363,364],"Anterior Cruciate Ligament Injuries","Analgesics, Opioid","2023-08-03",{"date":367,"type":31},"2023-08-14",{"date":365,"type":31},{"date":370,"type":20},"2026-08-03",{"name":37,"class":38},{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":92,"minAge":4,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":21,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":388,"leadSponsor":390,"locationsCount":70},"100481826","phase-2-immunogenicity-of-zoster-vaccine-in-allogeneic-hematopoietic-stem-cell-transplant-recipients-100481826","NCT05554068","Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","Phase II, Non-randomized, Open-label Study to Assess the Immunogenicity and Clinical Efficacy of the Recombinant Zoster Vaccine for Recipients of an Allogeneic Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n* Age ≥18 years\n* ≥ 12 months and ≤ 36 months post-AlloSCT\n* Donor sources: matched related, matched unrelated, cord blood\n* Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders.\n* Any conditioning regimen\n* Any planned immunosuppressive prophylactic regimen\n* Patients with chronic graft-versus-host disease on stable immunosuppression\n* Ability to understand and the willingness to sign a written informed consent.\n* Negative pregnancy test in female patients of childbearing potential\n\nExclusion Criteria:\n\n* Patients who had zoster after an allogeneic transplant and prior to enrollment\n* Patients who are currently pregnant\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study.\n* Patients who have had a relapse of their primary hematological disease\n* Previous allogeneic stem cell transplantation\n* Acute disease at the time of vaccination\n* Thrombocytopenia that in the judgment of the investigator would make intramuscular injection unsafe.",{"count":46,"type":20},[333],"This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.",[383],"Shingles","2023-03-07",{"date":386,"type":31},"2023-03-08",{"date":384,"type":31},{"date":389,"type":20},"2026-11-01",{"name":37,"class":38},{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":92,"minAge":16,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":401,"briefSummary":403,"conditions":404,"keywords":406,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":70},"100275820","phase-1-adoptive-t-cell-immunotherapy-for-advanced-melanoma-using-engineered-lymphocytes-100275820","NCT02870244","Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes","Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes: A Phase 1b Study","Inclusion Criteria:\n\n* Patients must have a diagnosis of metastatic melanoma which is evaluable either clinically or radiologically.\n* Patients must be 18 years of age or older.\n* Patients must consent to be in the study and must have signed and dated an approved consent form, which conforms to federal and institutional guidelines.\n* Patients must have a performance status (PS) of 0 or 1 ECOG PS scale.\n* Patients must have the ability to provide written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time.\n* Patients melanoma must be positive for both tyrosinase and HLA-A2 pathologic review from FNA, core or excisional biopsy of lesion.\n* Cardiac ejection fraction greater than 50 percent as determined by screening echocardiogram.\n* Patients that have undergone treatment with anti-CTLA-4, Cytotoxic T-Lymphocyte Antigen 4, antibody must have at least 6 weeks from last dose of CTLA-4 antibody and evidence of tumor progression before they can be enrolled into this study.\n* Patients that have undergone treatment with anti-PD-1, Programmed Death Receptor 1, Blockade or anti-PD-L1 antibody must have at least 4 weeks from last dose of antibody and evidence of tumor progression before they can be treated in this study.\n* Patients with V600E mutations are eligible if they have failed an approved BRAF inhibitor or MEK inhibitor therapy or have refused treatment with an approved BRAF inhibitor or MEK inhibitor.\n* Patients treated with prior Interleukin-2 (IL-2) are eligible.\n* Sufficient cardiopulmonary reserve for IL-2 per institutional guidelines.\n\nExclusion Criteria:\n\n* Special classes of subjects such as fetuses, pregnant women, children, prisoners, institutionalized individuals, or others who are likely to be vulnerable.\n* ECOG performance status of 2 or greater.\n* Patients with a history metastatic melanoma involving the brain will be excluded if they have active disease or have had active disease within the prior three months that was not controlled with surgery or radiotherapy.\n* Patients taking steroids for disease control or pain management\n* Patients must not be pregnant or nursing because of the potentially harmful effects of these agents on a developing fetus. Women or men of reproductive potential must have agreed to use an effective contraceptive method.\n* Patients whose BRAF V600 mutation status is unknown should undergo an attempt to determine this information, patients who have a BRAF V600 mutation and are responding to BRAF with or without MEK inhibitor therapy, or have a BRAF V600 mutation and have not been offered the option of receiving BRAF with or without MEK inhibitor therapy for the treatment of their melanoma are excluded.\n* No prior malignancy is allowed except for the following- adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for two years.\n* Patients that have undergone immunotherapy targeting tyrosinase.\n* Patients that have undergone immunotherapy in combination with non-myeloablative chemotherapy.\n* Any of the following abnormal laboratory values Absolute neutrophil count less than 1.5 x 10\\^9\u002FL Platelet count less than 100 x 10\\^9\u002FL Serum bilirubin greater than 1.5 x upper limit of normal ULN Serum ALT, AST greater than 2.5 x ULN Serum ALP greater than 2 x ULN Serum Albumin less than 2.5 g dL International Normalized Ratio, INR greater than 1.5 Serum creatinine calculated creatinine clearance by the method of Cockcroft and Gault, less than 50mL min.\n* Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics.\n* Any severe or poorly controlled systemic disease, for example hypertension, clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound-healing, ulcer or bone fracture.\n* Patients who have received any chemotherapy or investigational treatment within 4 weeks of study start.\n* Known infection with HIV, HBV, or HCV.\n* Known hypersensitivity to any of the components of the study drugs.\n* Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.","89 Years",{"count":400,"type":20},18,[402],"PHASE1","Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.",[405],"Melanoma",[405,407,408,409],"Gene Therapy","Adoptive T-Cell Transfer","IL-2","2018-03-08",{"date":412,"type":31},"2018-03-12",{"date":414,"type":31},"2015-02",{"date":416,"type":20},"2028-09",{"name":37,"class":38},""]